[go: up one dir, main page]

PL2970412T3 - Aktywacja bioluminescencji przez dopełnienie strukturalne - Google Patents

Aktywacja bioluminescencji przez dopełnienie strukturalne

Info

Publication number
PL2970412T3
PL2970412T3 PL14769752.8T PL14769752T PL2970412T3 PL 2970412 T3 PL2970412 T3 PL 2970412T3 PL 14769752 T PL14769752 T PL 14769752T PL 2970412 T3 PL2970412 T3 PL 2970412T3
Authority
PL
Poland
Prior art keywords
bioluminscence
activation
structural complement
complement
structural
Prior art date
Application number
PL14769752.8T
Other languages
English (en)
Inventor
Andrew S. Dixon
Lance Encell
Mary Hall
Keith Wood
Monika Wood
Marie SCHWINN
Brock F. Binkowski
Hicham Zegzouti
Nidhi Nath
Subhanjan Mondal
Said Goueli
Poncho Meisenheimer
Thomas Kirkland
James Unch
Dileep K. Pulukkunat
Matthew Robers
Melanie Dart
Thomas Machleidt
Original Assignee
Promega Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corporation filed Critical Promega Corporation
Publication of PL2970412T3 publication Critical patent/PL2970412T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0069Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00Commerce
    • G06Q30/02Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283Price estimation or determination
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00Commerce
    • G06Q30/06Buying, selling or leasing transactions
    • G06Q30/0601Electronic shopping [e-shopping]
    • G06Q30/0631Item recommendations
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02Services making use of location information
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30Services specially adapted for particular environments, situations or purposes
    • H04W4/35Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04WWIRELESS COMMUNICATION NETWORKS
    • H04W4/00Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30Services specially adapted for particular environments, situations or purposes
    • H04W4/38Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • Development Economics (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
PL14769752.8T 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne PL2970412T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15
PCT/US2014/026354 WO2014151736A1 (en) 2013-03-15 2014-03-13 Activation of bioluminescence by structural complementation

Publications (1)

Publication Number Publication Date
PL2970412T3 true PL2970412T3 (pl) 2022-11-14

Family

ID=51581027

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14769752.8T PL2970412T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne
PL20197758.4T PL3783011T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20197758.4T PL3783011T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Country Status (15)

Country Link
US (10) US9797890B2 (pl)
EP (4) EP3783011B1 (pl)
JP (4) JP6654557B2 (pl)
KR (3) KR20230079494A (pl)
CN (2) CN105143249A (pl)
AU (3) AU2014236949C1 (pl)
BR (1) BR112015023394B8 (pl)
CA (1) CA2906063A1 (pl)
DK (2) DK2970412T5 (pl)
ES (2) ES2929362T3 (pl)
IL (3) IL286816B (pl)
PL (2) PL2970412T3 (pl)
PT (2) PT2970412T (pl)
SG (2) SG10201601929YA (pl)
WO (1) WO2014151736A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3783011B1 (en) * 2013-03-15 2022-09-21 Promega Corporation Activation of bioluminescence by structural complementation
US20230342826A1 (en) * 2013-03-15 2023-10-26 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP3254113B1 (en) 2015-02-05 2024-10-09 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
KR102556363B1 (ko) * 2016-10-20 2023-07-18 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 보툴리눔 신경독소의 활성을 측정하기 위한 시험관내 및 세포 기반 검정
CA3022981A1 (en) * 2017-11-01 2019-05-01 Queen's University At Kingston Hippo pathway bioluminescent biosensor
JP7248693B2 (ja) * 2018-02-26 2023-03-29 テクニーシェ・ユニバーシタイト・アイントホーベン 溶液中の生物分子またはリガンドを検出し、定量化する生物発光バイオセンサー
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
WO2019241438A2 (en) * 2018-06-12 2019-12-19 Promega Corporation Multipartite luciferase
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
JP7447101B2 (ja) 2018-10-03 2024-03-11 プロメガ コーポレイション セレンテラジンならびにその類似体及び誘導体を安定化させるための組成物及び方法
JP2022509200A (ja) 2018-11-28 2022-01-20 プロメガ コーポレイション 反応性ペプチド標識付け
WO2020117954A2 (en) 2018-12-04 2020-06-11 Promega Corporation Broad spectrum gpcr binding agents
WO2020191339A1 (en) 2019-03-20 2020-09-24 Promega Corporation Photoaffinity probes
SG11202110773RA (en) * 2019-04-10 2021-10-28 Promega Corp Compositions and methods for analyte detection using bioluminescence
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
JP7650829B2 (ja) 2019-06-24 2025-03-25 プロメガ コーポレイション 細胞中に生体分子を送達するための修飾ポリアミンポリマー
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
WO2021102434A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
EP4065699A1 (en) 2019-11-27 2022-10-05 Promega Corporation Multipartite luciferase peptides and polypeptides
JP2023506486A (ja) 2019-12-10 2023-02-16 プロメガ コーポレイション 多官能性プローブを使用する生物発光検出用組成物及び生物発光検出方法
EP4127148A1 (en) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reporter system for radionuclide imaging
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
EP4153770A2 (en) 2020-05-22 2023-03-29 Promega Corporation Enhancement of kinase target engagement
EP4204808A1 (en) 2020-08-28 2023-07-05 Promega Corporation Target engagement assay for ras proteins
US20240252689A1 (en) * 2021-05-18 2024-08-01 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
WO2023215452A2 (en) 2022-05-04 2023-11-09 Promega Corporation Split modified dehalogenase variants
WO2023215432A1 (en) 2022-05-04 2023-11-09 Promega Corporation Circularly permuted dehalogenase variants
US20240132859A1 (en) 2022-05-04 2024-04-25 Promega Corporation Modified dehalogenase with extended surface loop regions
WO2023215497A1 (en) 2022-05-04 2023-11-09 Promega Corporation Photoactivatable compounds and uses thereof
WO2024151471A1 (en) 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
WO2024217577A1 (zh) * 2023-04-21 2024-10-24 深圳琅技生命科技有限公司 一种肽以及含有该肽的发光复合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
EP0664819B1 (en) 1992-10-14 1997-08-06 Nycomed Imaging As Chelating polymers
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
DE60142761D1 (de) * 2000-04-26 2010-09-23 Chisso Corp Oplophorus Luciferase
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
WO2004029284A2 (en) * 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
US20090149338A1 (en) 2005-09-30 2009-06-11 Hughes Thomas E System for detecting protein-protein interactions
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
US20130332133A1 (en) 2006-05-11 2013-12-12 Ramot At Tel Aviv University Ltd. Classification of Protein Sequences and Uses of Classified Proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
WO2009058364A1 (en) * 2007-11-01 2009-05-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell-free methods for detecting protein-ligand interctions
WO2009065002A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
JP5582505B2 (ja) 2009-02-09 2014-09-03 Jnc株式会社 セレンテラジン類縁体及びその製造方法
EP2420573A1 (en) 2009-04-17 2012-02-22 National Institute of Advanced Industrial Science And Technology Stable artificial bioluminescent enzyme having super-high brightness
SG175180A1 (en) 2009-05-01 2011-11-28 Promega Corp Synthetic oplophorus luciferases with enhanced light output
SG10202103336SA (en) * 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CA2894435A1 (en) * 2012-12-12 2014-06-19 Promega Corporation Recognition of cellular target binding by a bioactive agent using intracellular bioluminescence resonance energy transfer
EP3783011B1 (en) 2013-03-15 2022-09-21 Promega Corporation Activation of bioluminescence by structural complementation
EP4219736A1 (en) * 2014-09-12 2023-08-02 Promega Corporation Internal protein tags

Also Published As

Publication number Publication date
AU2020213288B2 (en) 2022-07-07
US20180095074A1 (en) 2018-04-05
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
IL240985B (en) 2020-05-31
US11493504B2 (en) 2022-11-08
US20180313825A1 (en) 2018-11-01
PT2970412T (pt) 2022-09-13
JP2024167207A (ja) 2024-12-03
US9797889B2 (en) 2017-10-24
AU2020213288A1 (en) 2020-08-27
EP2970412A1 (en) 2016-01-20
BR112015023394B8 (pt) 2023-09-26
WO2014151736A1 (en) 2014-09-25
US20180196038A1 (en) 2018-07-12
DK3783011T3 (da) 2022-10-17
EP4177261A1 (en) 2023-05-10
US9869670B2 (en) 2018-01-16
AU2018256548B2 (en) 2020-05-14
JP7280842B2 (ja) 2023-05-24
CN105143249A (zh) 2015-12-09
US20250045806A1 (en) 2025-02-06
KR102675860B1 (ko) 2024-06-20
US20250022022A1 (en) 2025-01-16
ES2929362T3 (es) 2022-11-28
PL3783011T3 (pl) 2022-11-21
BR112015023394A2 (pt) 2017-11-28
IL286816B (en) 2022-09-01
AU2014236949B2 (en) 2018-08-02
JP6654557B2 (ja) 2020-02-26
CA2906063A1 (en) 2014-09-25
JP2023055734A (ja) 2023-04-18
AU2018256548A1 (en) 2018-11-22
EP3783011B1 (en) 2022-09-21
EP2970412B1 (en) 2022-08-10
JP7532562B2 (ja) 2024-08-13
US10107800B2 (en) 2018-10-23
SG10201601929YA (en) 2016-04-28
EP4169935A1 (en) 2023-04-26
IL240985A0 (en) 2015-11-30
US10648971B2 (en) 2020-05-12
US20140348747A1 (en) 2014-11-27
KR20150129721A (ko) 2015-11-20
US20140363375A1 (en) 2014-12-11
AU2014236949A1 (en) 2015-09-24
US20180306782A1 (en) 2018-10-25
JP2016519065A (ja) 2016-06-30
DK3783011T5 (da) 2024-08-19
JP2020097597A (ja) 2020-06-25
IL273989A (en) 2020-05-31
US20160282340A1 (en) 2016-09-29
PT3783011T (pt) 2022-10-26
CN117024548A (zh) 2023-11-10
AU2014236949C1 (en) 2018-11-29
KR20210036422A (ko) 2021-04-02
DK2970412T3 (da) 2022-08-29
EP3783011A1 (en) 2021-02-24
ES2926463T3 (es) 2022-10-26
US20200292534A1 (en) 2020-09-17
KR20230079494A (ko) 2023-06-07
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
BR112015023394B1 (pt) 2023-08-29
US10184936B2 (en) 2019-01-22
EP2970412A4 (en) 2016-07-27
SG11201507306VA (en) 2015-10-29
IL273989B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
NL301252I2 (nl) tislelizumab
NL301278I2 (nl) vadadustat
PL2970412T3 (pl) Aktywacja bioluminescencji przez dopełnienie strukturalne
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK2978844T3 (da) Modificerede tgf-beta2-oligonukleotider
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK3077047T3 (da) Aramcholsalte
DK2956698T5 (da) Bindestrimler
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
EP2952513A4 (en) AZOLE AND BENZENE DERIVATIVE
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
EP2969096A4 (en) Bottle pressurization delivery system
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2970310A4 (en) 5-BROMO-indirubins
DE102013106534B8 (de) Chromatographiepipettenspitze
DK3071227T3 (da) Fiskevaccine
FI20136125A (fi) Rumpupulpperi
DE112014001252A5 (de) Aufbissschiene
DK2981168T3 (da) Laminitiskile
DK3086679T3 (da) Sportssko